Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile?

Stefano Crippa, Stefano Partelli, Giuseppe Zamboni, Giuliano Barugola, Paola Capelli, Marco Inama, Claudio Bassi, Paolo Pederzoli, Massimo Falconi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Poorly differentiated, resectable pancreatic ductal adenocarcinoma is associated with early recurrence and may benefit from neoadjuvant treatment. The aim of this study was to evaluate clinicopathologic characteristics and survival of patients with resectable pancreatic ductal adenocarcinoma according to histologic grading. Methods: A total of 502 patients who underwent resection for pancreatic ductal adenocarcinoma between 1990 and 2008 were analyzed via the use of different histologic grading. Results: Well-differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) pancreatic ductal adenocarcinomas were found in 23 (4.5%), 310 (62%), and 169 (33.5%) patients. Adjuvant therapy, N status, grading, and R status were independent predictors of disease-specific survival for the entire cohort, with 1- and 5-year disease-specific survival rates of 81% and 21%, respectively. Only the presence of symptoms was a significant clinical predictor of G3 status (P = .035). G3 neoplasms were characterized by a greater rate of lymph node metastases, microvascular/perineural invasion, and R2 resections. Median disease-specific survival was 77, 26, and 20 months for G1, G2, and G3 neoplasms (P <.0001). Median disease-free survival was 63, 14, and 9 months for G1, G2, and G3 pancreatic ductal adenocarcinoma (P <.0001). Adjuvant therapy improved disease-specific survival in G2 (P <.04) and G3 (P <.0001) pancreatic ductal adenocarcinoma, with a greater survival benefit for G3 neoplasms (hazard ratio: 1.334 vs 2.116). Conclusion: G3 pancreatic ductal adenocarcinoma is associated with a lesser rate of disease-free survival after resection and with the presence of other poor prognostic factors. The benefit of adjuvant therapy is greater in G3 than in G1 and G2 neoplasms. On the basis of these findings, patients with resectable G3 PDAC can be considered as possible targets for neoadjuvant treatment.

Original languageEnglish
JournalSurgery
Volume152
Issue number3 SUPPL.
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Survival
Neoadjuvant Therapy
Disease-Free Survival
Neoplasms
Therapeutics
Survival Rate
Lymph Nodes
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Surgery

Cite this

Crippa, S., Partelli, S., Zamboni, G., Barugola, G., Capelli, P., Inama, M., ... Falconi, M. (2012). Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile? Surgery, 152(3 SUPPL.). https://doi.org/10.1016/j.surg.2012.05.017

Poorly differentiated resectable pancreatic cancer : Is upfront resection worthwhile? / Crippa, Stefano; Partelli, Stefano; Zamboni, Giuseppe; Barugola, Giuliano; Capelli, Paola; Inama, Marco; Bassi, Claudio; Pederzoli, Paolo; Falconi, Massimo.

In: Surgery, Vol. 152, No. 3 SUPPL., 09.2012.

Research output: Contribution to journalArticle

Crippa, S, Partelli, S, Zamboni, G, Barugola, G, Capelli, P, Inama, M, Bassi, C, Pederzoli, P & Falconi, M 2012, 'Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile?', Surgery, vol. 152, no. 3 SUPPL.. https://doi.org/10.1016/j.surg.2012.05.017
Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M et al. Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile? Surgery. 2012 Sep;152(3 SUPPL.). https://doi.org/10.1016/j.surg.2012.05.017
Crippa, Stefano ; Partelli, Stefano ; Zamboni, Giuseppe ; Barugola, Giuliano ; Capelli, Paola ; Inama, Marco ; Bassi, Claudio ; Pederzoli, Paolo ; Falconi, Massimo. / Poorly differentiated resectable pancreatic cancer : Is upfront resection worthwhile?. In: Surgery. 2012 ; Vol. 152, No. 3 SUPPL.
@article{f9ca1a25f3d14b3d8da8675af83c8097,
title = "Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile?",
abstract = "Background: Poorly differentiated, resectable pancreatic ductal adenocarcinoma is associated with early recurrence and may benefit from neoadjuvant treatment. The aim of this study was to evaluate clinicopathologic characteristics and survival of patients with resectable pancreatic ductal adenocarcinoma according to histologic grading. Methods: A total of 502 patients who underwent resection for pancreatic ductal adenocarcinoma between 1990 and 2008 were analyzed via the use of different histologic grading. Results: Well-differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) pancreatic ductal adenocarcinomas were found in 23 (4.5{\%}), 310 (62{\%}), and 169 (33.5{\%}) patients. Adjuvant therapy, N status, grading, and R status were independent predictors of disease-specific survival for the entire cohort, with 1- and 5-year disease-specific survival rates of 81{\%} and 21{\%}, respectively. Only the presence of symptoms was a significant clinical predictor of G3 status (P = .035). G3 neoplasms were characterized by a greater rate of lymph node metastases, microvascular/perineural invasion, and R2 resections. Median disease-specific survival was 77, 26, and 20 months for G1, G2, and G3 neoplasms (P <.0001). Median disease-free survival was 63, 14, and 9 months for G1, G2, and G3 pancreatic ductal adenocarcinoma (P <.0001). Adjuvant therapy improved disease-specific survival in G2 (P <.04) and G3 (P <.0001) pancreatic ductal adenocarcinoma, with a greater survival benefit for G3 neoplasms (hazard ratio: 1.334 vs 2.116). Conclusion: G3 pancreatic ductal adenocarcinoma is associated with a lesser rate of disease-free survival after resection and with the presence of other poor prognostic factors. The benefit of adjuvant therapy is greater in G3 than in G1 and G2 neoplasms. On the basis of these findings, patients with resectable G3 PDAC can be considered as possible targets for neoadjuvant treatment.",
author = "Stefano Crippa and Stefano Partelli and Giuseppe Zamboni and Giuliano Barugola and Paola Capelli and Marco Inama and Claudio Bassi and Paolo Pederzoli and Massimo Falconi",
year = "2012",
month = "9",
doi = "10.1016/j.surg.2012.05.017",
language = "English",
volume = "152",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Poorly differentiated resectable pancreatic cancer

T2 - Is upfront resection worthwhile?

AU - Crippa, Stefano

AU - Partelli, Stefano

AU - Zamboni, Giuseppe

AU - Barugola, Giuliano

AU - Capelli, Paola

AU - Inama, Marco

AU - Bassi, Claudio

AU - Pederzoli, Paolo

AU - Falconi, Massimo

PY - 2012/9

Y1 - 2012/9

N2 - Background: Poorly differentiated, resectable pancreatic ductal adenocarcinoma is associated with early recurrence and may benefit from neoadjuvant treatment. The aim of this study was to evaluate clinicopathologic characteristics and survival of patients with resectable pancreatic ductal adenocarcinoma according to histologic grading. Methods: A total of 502 patients who underwent resection for pancreatic ductal adenocarcinoma between 1990 and 2008 were analyzed via the use of different histologic grading. Results: Well-differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) pancreatic ductal adenocarcinomas were found in 23 (4.5%), 310 (62%), and 169 (33.5%) patients. Adjuvant therapy, N status, grading, and R status were independent predictors of disease-specific survival for the entire cohort, with 1- and 5-year disease-specific survival rates of 81% and 21%, respectively. Only the presence of symptoms was a significant clinical predictor of G3 status (P = .035). G3 neoplasms were characterized by a greater rate of lymph node metastases, microvascular/perineural invasion, and R2 resections. Median disease-specific survival was 77, 26, and 20 months for G1, G2, and G3 neoplasms (P <.0001). Median disease-free survival was 63, 14, and 9 months for G1, G2, and G3 pancreatic ductal adenocarcinoma (P <.0001). Adjuvant therapy improved disease-specific survival in G2 (P <.04) and G3 (P <.0001) pancreatic ductal adenocarcinoma, with a greater survival benefit for G3 neoplasms (hazard ratio: 1.334 vs 2.116). Conclusion: G3 pancreatic ductal adenocarcinoma is associated with a lesser rate of disease-free survival after resection and with the presence of other poor prognostic factors. The benefit of adjuvant therapy is greater in G3 than in G1 and G2 neoplasms. On the basis of these findings, patients with resectable G3 PDAC can be considered as possible targets for neoadjuvant treatment.

AB - Background: Poorly differentiated, resectable pancreatic ductal adenocarcinoma is associated with early recurrence and may benefit from neoadjuvant treatment. The aim of this study was to evaluate clinicopathologic characteristics and survival of patients with resectable pancreatic ductal adenocarcinoma according to histologic grading. Methods: A total of 502 patients who underwent resection for pancreatic ductal adenocarcinoma between 1990 and 2008 were analyzed via the use of different histologic grading. Results: Well-differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) pancreatic ductal adenocarcinomas were found in 23 (4.5%), 310 (62%), and 169 (33.5%) patients. Adjuvant therapy, N status, grading, and R status were independent predictors of disease-specific survival for the entire cohort, with 1- and 5-year disease-specific survival rates of 81% and 21%, respectively. Only the presence of symptoms was a significant clinical predictor of G3 status (P = .035). G3 neoplasms were characterized by a greater rate of lymph node metastases, microvascular/perineural invasion, and R2 resections. Median disease-specific survival was 77, 26, and 20 months for G1, G2, and G3 neoplasms (P <.0001). Median disease-free survival was 63, 14, and 9 months for G1, G2, and G3 pancreatic ductal adenocarcinoma (P <.0001). Adjuvant therapy improved disease-specific survival in G2 (P <.04) and G3 (P <.0001) pancreatic ductal adenocarcinoma, with a greater survival benefit for G3 neoplasms (hazard ratio: 1.334 vs 2.116). Conclusion: G3 pancreatic ductal adenocarcinoma is associated with a lesser rate of disease-free survival after resection and with the presence of other poor prognostic factors. The benefit of adjuvant therapy is greater in G3 than in G1 and G2 neoplasms. On the basis of these findings, patients with resectable G3 PDAC can be considered as possible targets for neoadjuvant treatment.

UR - http://www.scopus.com/inward/record.url?scp=84865221312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865221312&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2012.05.017

DO - 10.1016/j.surg.2012.05.017

M3 - Article

C2 - 22766365

AN - SCOPUS:84865221312

VL - 152

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 3 SUPPL.

ER -